Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

Core Insights - Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for serious, rare genetic skin diseases without FDA-approved treatments [1][3] - The company will have its CEO, Wes Kaupinen, participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025 [1] - Palvella's lead product candidate, QTORIN™ rapamycin, is currently in Phase 3 and Phase 2 clinical trials for specific conditions [3] Company Overview - Palvella Therapeutics is led by veterans in rare disease drug development and is focused on a broad pipeline of product candidates based on its patented QTORIN™ platform [3] - The company is specifically targeting serious, rare genetic skin diseases, many of which are lifelong [3] - QTORIN™ rapamycin is under investigation for microcystic lymphatic malformations and cutaneous venous malformations [3] Event Information - A live webcast of the fireside chat will be available on Palvella's website, with an archived replay accessible for approximately 90 days [2]